Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec:179:114035.
doi: 10.1016/j.addr.2021.114035. Epub 2021 Nov 2.

Smart biomaterials to enhance the efficiency of immunotherapy in glioblastoma: State of the art and future perspectives

Banafshe Abadi  1 , Niloufar Yazdanpanah  2 , Ali Nokhodchi  3 , Nima Rezaei  4
Affiliations
Review

Smart biomaterials to enhance the efficiency of immunotherapy in glioblastoma: State of the art and future perspectives

Banafshe Abadi et al. Adv Drug Deliv Rev. 2021 Dec.

Abstract

Glioblastoma multiform (GBM) is considered as the most lethal tumor among CNS malignancies. Although immunotherapy has achieved remarkable advances in cancer treatment, it has not shown satisfactory results in GBM patients. Biomaterial science, along with nanobiotechnology, is able to optimize the efficiency of immunotherapy in these patients. They can be employed to provide the specific activation of immune cells in tumor tissue and combinational therapy as well as preventing systemic adverse effects resulting from hyperactivation of immune responses and off-targeting effect. Advance biomaterials in this field are classified into targeting nanocarriers and localized delivery systems. This review will offer an overview of immunotherapy strategies for glioblastoma and advance delivery systems for immunotherapeutics that may have a high potential in glioblastoma treatment.

Keywords: Biomaterial; Combinational therapy; Glioblastoma; Immunotherapy; Localized delivery systems; Nanotechnology.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

MeSH terms